Cargando…
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation, systemic inflammation, and immunological abnormalities. Because cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 play a major role in the development of RA, their targeti...
Autores principales: | Tanaka, Toshio, Hishitani, Yoshihiro, Ogata, Atsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984066/ https://www.ncbi.nlm.nih.gov/pubmed/24741293 http://dx.doi.org/10.2147/BTT.S37509 |
Ejemplares similares
-
Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012) -
Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions
por: Ogata, Atsushi, et al.
Publicado: (2012) -
346 Clinical Effects of Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, on Patients with Autoimmune and Allergic Diseases
por: Tanaka, Toshio, et al.
Publicado: (2012) -
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018) -
Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors
por: Kobayashi, Tetsuo, et al.
Publicado: (2015)